Definium Therapeutics' oral LSD candidate succeeds in initial Phase 3 trial for generalized anxiety disorder
Definium Therapeutics announced that its oral LSD-based drug met the primary endpoint in a Phase 3 study for generalized anxiety disorder. This success comes less than two months after the same asset showed positive results in a severe form of anxiety. The company still awaits results from a second Phase 3 trial.
Related stories
LSD-based treatment shows promise for generalized anxiety disorder in late-stage trial · Mental health
Zipalertinib succeeds in Phase 3 trial for EGFR-mutant lung cancer, challenging Rybrevant · Cancer research
This summary is AI-generated and original to Mobble; the linked article is the authoritative source.
Original headline: “Definium's LSD drug clears bar in first of two Phase 3 anxiety disorder trials.” Browse more stories.